• Explore /
  • Poster
  • / Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.

Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.

Abstract Poster

Authors

null

Gunnar Folprecht

University Hospital Carl Gustav Carus, Medical Department I/University Cancer Center, Dresden, Germany

Gunnar Folprecht , Thomas Gruenberger , Wolf Bechstein , Florian Lordick , Hauke Lang , Jürgen Weitz , Thomas Suedhoff , Joerg Thomas Hartmann , Torsten Liersch , Claus-Henning Kohne

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00153998

Citation

J Clin Oncol 30, 2012 (suppl 4; abstr 540)

DOI

10.1200/jco.2012.30.4_suppl.540

Abstract #

540

Poster Bd #

D15

Abstract Disclosures

Similar Posters

First Author: Gunnar Folprecht

Poster

2016 Gastrointestinal Cancers Symposium

Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials.

Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials.

First Author: Sarah Chrabaszcz

First Author: Qi Lin

First Author: Frank A. Sinicrope